The History of Vitamin C Megadosing
The History of Vitamin C Megadosing
Written on 24 August 2026.
Vitamin C megadosing did not begin with Thomas E. Levy. Levy became one of its most prominent modern advocates, but the use of vitamin C in gram-level quantities—and sometimes in very large intravenous doses—had already developed over several decades.
The history includes physicians, biochemists and researchers such as Frederick Klenner, Irwin Stone, Linus Pauling, Ewan Cameron, Robert Cathcart and Abram Hoffer. Their work covered infectious diseases, cancer, general health, psychiatric conditions and withdrawal from addictive drugs.
From a deficiency vitamin to a therapeutic substance
Vitamin C was originally understood chiefly as the substance needed to prevent scurvy. This produced a nutritional model in which relatively small daily amounts were considered sufficient.
Advocates of megadosing proposed a different model. They argued that the amount required to prevent an obvious deficiency disease might be much lower than the amount useful during infection, injury, poisoning or other forms of physiological stress.
This distinction became central to megadose vitamin C:
- A nutritional dose prevents scurvy.
- A larger supplemental dose may maintain higher vitamin C availability.
- A therapeutic dose is intended to affect an existing illness or physiological crisis.
These categories remain controversial because preventing deficiency is well established, whereas many proposed therapeutic uses have not been conclusively demonstrated.
Frederick Klenner and high-dose vitamin C
One of the earliest major practitioners was the American physician Frederick R. Klenner. During the 1940s, Klenner reported using frequent oral, intramuscular and intravenous vitamin C against infectious diseases.
His publications included:
- Virus Pneumonia and Its Treatment with Vitamin C (1948)
- The Treatment of Poliomyelitis and Other Virus Diseases with Vitamin C (1949)
- Observations on the Dose and Administration of Ascorbic Acid When Employed Beyond the Range of a Vitamin in Human Pathology (1971)
Klenner emphasized not only the total quantity but also the frequency and route of administration. He believed earlier experiments had failed because they employed doses that were too small or administered too infrequently.
In later writings, he described using many grams intravenously, sometimes reaching extremely large quantities over a twenty-four-hour period. He also recommended frequent oral administration after the initial intravenous treatment.
Klenner’s reports are historically important because they demonstrate that medical megadosing existed long before Thomas Levy’s books. However, much of Klenner’s evidence consisted of clinical observations and case reports rather than randomized controlled trials. His reported outcomes therefore cannot automatically be regarded as scientifically established cures.
Irwin Stone and hypoascorbemia
Biochemist Irwin Stone developed a theoretical foundation for long-term high vitamin C intake. Stone pointed out that most mammals manufacture vitamin C internally, whereas humans and some other species cannot.
He described the human condition as hypoascorbemia. In his view, the human inability to synthesize vitamin C was a genetic defect that left people chronically supplied with less ascorbate than would be physiologically optimal.
Stone reportedly introduced Linus Pauling to high-dose vitamin C in 1966. Stone’s contribution was therefore important both theoretically and historically: he helped move the discussion from vitamin C as merely an anti-scurvy nutrient toward vitamin C as a substance that might be required in gram-level quantities.
Linus Pauling popularizes megadosing
Linus Pauling brought megadose vitamin C to a much larger public. His book Vitamin C and the Common Cold, published in 1970, argued that supplemental vitamin C could reduce the occurrence or severity of colds.
Pauling initially recommended amounts around one or two grams daily, although he later discussed higher and individually varying intakes. These doses were far above the amount required merely to prevent scurvy.
Pauling did not originate vitamin C megadosing. Klenner had already been using and writing about large doses for more than twenty years. Nevertheless, Pauling transformed megadosing from a relatively obscure medical practice into an internationally recognized—and highly controversial—health movement.
Controlled research has not supported all of Pauling’s claims. Vitamin C does not appear to prevent ordinary colds in most people, although regular supplementation may modestly shorten their duration. The results can also differ according to the population studied, dose, frequency and whether supplementation begins before or after symptoms appear.
Ewan Cameron, Linus Pauling and cancer
During the 1970s, Scottish surgeon Ewan Cameron and Linus Pauling investigated vitamin C as supportive treatment for terminal cancer patients.
Their patients generally received approximately 10 grams daily. The treatment initially included intravenous vitamin C, followed by continued oral supplementation. Cameron and Pauling reported substantially longer survival among treated patients than among retrospectively selected control patients.
Later randomized studies conducted at the Mayo Clinic did not reproduce the claimed survival benefit. However, those trials primarily tested oral vitamin C rather than reproducing the intravenous-then-oral protocol. This distinction later became important because intravenous administration can produce much higher blood concentrations than oral supplementation.
The Cameron–Pauling work remains controversial. It did not prove that vitamin C cures cancer, but it helped establish the continuing scientific question of whether pharmacological intravenous ascorbate might have effects fundamentally different from ordinary oral supplementation.
Robert Cathcart and bowel tolerance
Physician Robert F. Cathcart developed the concept of titrating oral vitamin C to bowel tolerance. His method involved taking divided doses until reaching an amount just below that which caused loose stools or diarrhoea.
Cathcart observed that people appeared able to tolerate more oral vitamin C during illness than when healthy. He interpreted this as evidence that infection and physiological stress increased the body’s use of ascorbate.
His 1981 paper, Vitamin C, Titrating to Bowel Tolerance, Anascorbemia, and Acute Induced Scurvy, formally described this approach.
Cathcart’s method emphasized that frequency matters. A large amount taken all at once is poorly absorbed and more likely to produce gastrointestinal symptoms. Dividing the same total amount into frequent doses may sustain availability while improving tolerance.
This is historically relevant to modern discussions about taking vitamin C every few hours rather than consuming the entire daily quantity in one or two doses. Nevertheless, bowel tolerance is not a validated measurement of the dose needed to treat a particular disease.
Abram Hoffer and orthomolecular medicine
Canadian psychiatrist Abram Hoffer became another major figure in orthomolecular medicine. Hoffer used large doses of vitamins, particularly niacin and vitamin C, in programmes addressing psychiatric illness, alcoholism and drug dependence.
In recorded interviews, Hoffer claimed that people addicted to drugs could recover with nutritional treatment and experience greatly reduced—or even absent—withdrawal symptoms. His programmes generally involved more than vitamin C alone. They could include:
- Niacin
- Vitamin C
- Other vitamins and minerals
- Protein and dietary changes
- Removal of refined sugar and nutritionally poor foods
Consequently, Hoffer’s reports cannot establish that vitamin C alone eliminated withdrawal. They should be understood as observations concerning a broader orthomolecular programme.
High-dose niacin also has risks that differ from those of vitamin C. Depending on the form and dose, it can cause flushing, liver injury, elevated blood sugar and increased uric acid. Hoffer-style niacin treatment should therefore not be treated as ordinary unsupervised vitamin supplementation.
Vitamin C and heroin withdrawal
The use of vitamin C during heroin withdrawal is an especially interesting but relatively neglected part of megadosing history.
The Libby–Stone pilot study
In 1977, Alfred F. Libby and Irwin Stone reported a pilot programme involving 30 people withdrawing from heroin or methadone. Their programme reportedly used:
- 25–85 grams of sodium ascorbate daily during the initial period
- Divided oral doses
- Supplemental protein
- Additional vitamins and minerals
- Reduced maintenance doses after the first several days
Libby and Stone claimed that withdrawal symptoms were greatly reduced and sometimes absent.
These results were remarkable, but the study had serious limitations. It lacked a proper randomized control group, involved only a small number of patients and combined vitamin C with protein and other nutrients. It therefore provides historical and hypothesis-generating evidence rather than conclusive proof.
The Evangelou study
A more formal human study was published by Angelos Evangelou and colleagues in 2000 under the title Ascorbic Acid (Vitamin C) Effects on Withdrawal Syndrome of Heroin Abusers.
The researchers administered:
- Vitamin C at 300 milligrams per kilogram of body weight per day
- Vitamin E at 5 milligrams per kilogram per day
- Treatment for at least four weeks
For a person weighing 70 kilograms, the vitamin C amount would equal approximately 21 grams per day.
The study included 30 male inpatients receiving vitamin C and vitamin E together with conventional withdrawal medication, ten outpatients receiving the vitamins, and 30 inpatient controls receiving conventional medication without the added vitamins.
Major withdrawal symptoms were reported in approximately 10–16.6 percent of the vitamin-treated participants, compared with 56.6 percent of controls. The researchers concluded that high-dose oral vitamin C may ameliorate heroin withdrawal and called for additional studies.
This study supports the possibility that vitamin C could reduce withdrawal severity. It does not establish that vitamin C alone prevents withdrawal because vitamin E and, among the inpatients, conventional medication were also used. The study was small, and its findings have not been confirmed through a large programme of replicated clinical trials.
Thomas Levy’s place in the history
Thomas E. Levy’s book Vitamin C, Infectious Diseases, and Toxins appeared in 2002. By then, the history of megadose vitamin C already included:
- Klenner’s infectious-disease treatments beginning in the 1940s
- Stone’s hypoascorbemia theory
- Pauling’s public advocacy beginning in 1970
- Cameron and Pauling’s cancer work during the 1970s
- Libby and Stone’s 1977 addiction pilot study
- Cathcart’s bowel-tolerance method
- Hoffer’s orthomolecular addiction and psychiatric programmes
- The 2000 heroin-withdrawal study
Levy therefore did not invent megadose vitamin C. His contribution was principally to collect earlier reports, interpret them within an antioxidant and toxin-centred framework, and promote vitamin C as a broadly applicable therapeutic substance.
Oral and intravenous vitamin C are not equivalent
A recurring difficulty in evaluating vitamin C research is the failure to distinguish between oral and intravenous administration.
Oral absorption is regulated by the digestive system. As an oral dose increases, the percentage absorbed generally decreases, while gastrointestinal side effects become more likely. Intravenous administration bypasses intestinal absorption and can produce blood concentrations many times higher than oral dosing.
Consequently, a failed trial of oral vitamin C does not necessarily answer a claim made specifically about intravenous vitamin C. Conversely, results obtained intravenously cannot be assumed to apply to ordinary oral supplements.
There are therefore at least three separate questions:
- Does regular oral vitamin C provide nutritional or preventive benefits?
- Can frequent high oral doses alter the course of an existing illness?
- Can pharmacological intravenous concentrations produce effects unavailable through oral dosing?
These questions require separate evidence.
Safety and evidential limits
Vitamin C has a relatively wide safety margin, but relatively safe does not mean incapable of causing harm.
Large oral quantities commonly cause:
- Diarrhoea
- Abdominal cramping
- Nausea
- Fluid and electrolyte loss
High-dose vitamin C may also increase urinary oxalate. Particular caution is warranted in people with kidney disease, a history of calcium-oxalate kidney stones, iron-overload disorders or glucose-6-phosphate dehydrogenase deficiency. Intravenous vitamin C requires medical screening and supervision.
Opioid withdrawal presents additional dangers. Diarrhoea and vomiting can cause dehydration, and a person who returns to heroin or fentanyl after losing tolerance faces an increased risk of fatal overdose. Vitamin C should therefore not be presented as a proven substitute for supervised withdrawal care or established addiction treatment.
Conclusion
The history of vitamin C megadosing is much older than Thomas Levy’s books. It developed through the clinical reports of Frederick Klenner, the biochemical theories of Irwin Stone, the public advocacy of Linus Pauling, the cancer work of Ewan Cameron, Robert Cathcart’s bowel-tolerance method and the orthomolecular programmes of Abram Hoffer.
The experiments involving heroin withdrawal show that megadose vitamin C was not limited to colds or cancer. Researchers and practitioners also investigated whether large, divided doses could reduce the physiological distress of drug withdrawal. The reported results were promising enough to justify further research, but the limited and often uncontrolled evidence does not establish vitamin C as a complete treatment for addiction.
The most historically accurate conclusion is therefore neither that megadose vitamin C has been conclusively proven to cure a vast range of diseases nor that the entire subject began with modern advocates such as Thomas Levy. It is a longstanding medical hypothesis supported by some laboratory research, small clinical studies and numerous case reports, but with major claims that still require stronger controlled evidence.
AI Disclosure: Parts of this page may have been created, edited, or assisted by artificial intelligence tools (such as ChatGPT or other language models). All AI-assisted content is reviewed by a human before publication. For questions, contact the site administrator.